Journal of Clinical Oncology - ASCO Publications
WEBSep 9, 2024 · A world where cancer is prevented or cured. Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. Through research, education, and promotion of the highest-quality, equitable patient care, ASCO works to conquer cancer and create a world where cancer is …
Management of Stage III Non–Small-Cell Lung Cancer: ASCO …
WEBDec 22, 2021 · PURPOSE To provide evidence-based recommendations to practicing clinicians on management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An Expert Panel of medical oncology, thoracic surgery, radiation oncology, pulmonary oncology, community oncology, research methodology, and advocacy …
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
WEBOct 17, 2022 · Perioperative chemotherapy is recommended for a total preoperative and postoperative duration of 6 months, on the basis of total duration of chemotherapy in the EORTC 40983 trial. 64. Table 10. Perioperative Chemotherapy Versus Surgery Alone for Patients With Liver Metastases From Colorectal Cancer 22. Open in viewer.
Management of Immune-Related Adverse Events in Patients …
WEBPURPOSE To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitor (ICPi) therapy. METHODS A multidisciplinary panel of medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, …
Gastroesophageal Junction Adenocarcinoma: Is There an Optimal ...
WEBMay 17, 2019 · The incidence of gastroesophageal junction (GEJ) adenocarcinomas has been rising over the past few decades, creating a need for effective therapeutic strategies. Treatment of locally advanced GEJ tumors, in particular, present a unique challenge because these tumors have generally been approached as either esophageal or gastric …
ASCO Daily News
WEBPodcast: Key Takeaways From 2024 ASCO Breakthrough. Dr. Lillian Siu and Dr. Melvin Chua discuss the new technologies and novel therapeutics that were featured at the 2024 ASCO Breakthrough meeting. More ASCO Daily News Podcasts.
Latest Advances in the Diagnosis and Treatment of Large Granular ...
WEBMay 23, 2018 · Large granular lymphocyte (LGL) leukemia is an indolent lymphoproliferative disorder that belongs to mature T and natural killer (NK) cell neoplasms and is recognized as cytotoxic T and NK cell lymphomas and leukemia in the 2016 World Health Organization classification. 1 Two subtypes of chronic LGL proliferation are described, T-LGL and NK …
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted …
WEBJan 28, 2021 · PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended care options. RESULTS A total of 41 articles met eligibility criteria …
Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline
WEBPURPOSE To provide guidance to clinicians regarding therapy for patients with brain metastases from solid tumors. METHODS ASCO convened an Expert Panel and conducted a systematic review of the literature. RESULTS Thirty-two randomized trials published in 2008 or later met eligibility criteria and form the primary evidentiary base. …
Prevention and Management of Chemotherapy-Induced …
WEBJul 14, 2020 · PURPOSE To update the ASCO guideline on the recommended prevention and treatment approaches in the management of chemotherapy-induced peripheral neuropathy (CIPN) in adult cancer survivors. METHODS An Expert Panel conducted targeted systematic literature reviews to identify new studies. RESULTS The search …